AstraZeneca PLC (AZN)
75.44
+4.24
(+5.96%)
USD |
NASDAQ |
Apr 25, 12:45
AstraZeneca Research and Development Expense (TTM): 10.94B for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 10.94B |
| September 30, 2023 | 10.49B |
| June 30, 2023 | 10.36B |
| March 31, 2023 | 10.24B |
| December 31, 2022 | 9.762B |
| September 30, 2022 | 9.721B |
| June 30, 2022 | 10.87B |
| March 31, 2022 | 10.16B |
| December 31, 2021 | 9.736B |
| September 30, 2021 | 8.871B |
| June 30, 2021 | 6.756B |
| March 31, 2021 | 6.316B |
| December 31, 2020 | 5.991B |
| September 30, 2020 | 6.363B |
| June 30, 2020 | 6.214B |
| March 31, 2020 | 6.181B |
| December 31, 2019 | 6.059B |
| September 30, 2019 | 6.075B |
| June 30, 2019 | 5.971B |
| March 31, 2019 | 5.977B |
| December 31, 2018 | 5.99B |
| September 30, 2018 | 5.434B |
| June 30, 2018 | 5.596B |
| March 31, 2018 | 5.583B |
| December 31, 2017 | 5.757B |
| Date | Value |
|---|---|
| September 30, 2017 | 5.749B |
| June 30, 2017 | 5.747B |
| March 31, 2017 | 5.863B |
| December 31, 2016 | 5.89B |
| September 30, 2016 | 6.093B |
| June 30, 2016 | 6.12B |
| March 31, 2016 | 6.121B |
| December 31, 2015 | 5.997B |
| September 30, 2015 | 5.75B |
| June 30, 2015 | 5.873B |
| March 31, 2015 | 5.735B |
| December 31, 2014 | 5.579B |
| September 30, 2014 | 5.509B |
| June 30, 2014 | 4.815B |
| March 31, 2014 | 4.762B |
| December 31, 2013 | 4.821B |
| September 30, 2013 | 4.712B |
| June 30, 2013 | 5.058B |
| March 31, 2013 | 4.972B |
| December 31, 2012 | 5.243B |
| September 30, 2012 | 5.79B |
| June 30, 2012 | 5.882B |
| March 31, 2012 | 5.891B |
| December 31, 2011 | 5.523B |
| September 30, 2011 | 5.586B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
5.971B
Minimum
Jun 2019
10.94B
Maximum
Dec 2023
8.267B
Average
8.871B
Median
Sep 2021
Research and Development Expense (TTM) Benchmarks
| GSK PLC | 7.747B |
| Amgen Inc | 4.784B |
| Sanofi SA | 7.283B |
| Viking Therapeutics Inc | 63.81M |
| Fusion Pharmaceuticals Inc | 70.10M |